Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

NCCN bone health task force: key recommendations.

Azeez Farooki1

  • 1Presented by Azeez Farooki, MD, from Memorial Sloan-Kettering Cancer Center, New York, New York.

Journal of the National Comprehensive Cancer Network : JNCCN
|May 24, 2014
PubMed
Summary

Antiresorptive therapies are standard for bone health in advanced cancer patients, but clinicians must monitor for rare adverse events. Discussions covered screening, drug holidays, potential anticancer effects, and safety of supplements.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer.

The Journal of clinical endocrinology and metabolism·2026
Same author

Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer.

JCO oncology practice·2025
Same author

Bone health in cancer: perspective on the use of osteoanabolic agents.

Therapeutic advances in endocrinology and metabolism·2025
Same author

Teriparatide as an adjuvant therapy in the management of advanced-stage medication-related osteonecrosis of the jaw.

Oral surgery, oral medicine, oral pathology and oral radiology·2025
Same author

A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.

Breast cancer research : BCR·2024
Same author

Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique.

NPJ breast cancer·2024

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Standard care for bone health in advanced cancers involves antiresorptive agents like bisphosphonates, SERMs, and denosumab.
  • These therapies offer significant benefits, but potential long-term adverse events, though rare, require clinical awareness.

Discussion:

  • Key topics included osteoporosis screening protocols.
  • The use and implications of drug holidays for chronic bisphosphonate therapy were debated.
  • The potential anticancer benefits of antiresorptive agents remain an area of ongoing research.

Key Insights:

  • Imaging modalities for metastatic bone disease were reviewed.
  • Safety considerations for calcium and vitamin D supplementation were highlighted.
  • The NCCN Bone Health Task Force presented findings on managing bone health in cancer patients.

Outlook:

  • Further research is needed to clarify the anticancer potential of antiresorptive agents.
  • Optimizing safety profiles for bone-modifying therapies remains a priority.
  • Continued vigilance and evidence-based guidelines are essential for patient care.

Related Experiment Videos